Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease.
Steffen BankMette JulsgaardOsama Karim AbedBurisch JJacob Broder BrodersenNatalia Konstantinovich PedersenAnja GouliaevRullah AjanDitlev Nytoft RasmussenCamilla Honore GrauslundStine RougJulie GalsgaardDavid Sprogøe Høyer FinsenKaroline Lindbynull nullJeanette SørensenLone LarsenMalene Rohr AndersenIvan BrandslundMads ThomassenAnders GreenAnders Bo BojesenSigne Bek SørensenUlla VogelVibeke AndersenPublished in: Alimentary pharmacology & therapeutics (2019)
The results support that polymorphisms in genes involved in the regulation of the NFκB pathway (TLR2, TLR4, and NFKBIA), the TNF-α signalling pathway (TNFRSF1A), and other cytokine pathways (NLRP3, IL1RN, IL18, and JAK2) were associated with response to anti-TNF therapy. Our multi-SNP model predicted response rate of more than 82% (in 9% of the CD patients) and 75% (in 15% of the UC patients), compared to 71% and 64% in all CD and UC patients, respectively. More studies are warranted to predict response for use in the clinic.